Atea Pharmaceuticals, Inc.
AVIR
$3.17
-$0.04-1.25%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -139.49M | -168.39M | -174.01M | -176.00M | -163.66M |
| Total Depreciation and Amortization | 416.00K | 416.00K | 416.00K | 416.00K | 416.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 36.06M | 39.95M | 36.17M | 34.67M | 33.63M |
| Change in Net Operating Assets | -23.18M | -7.48M | 10.48M | 19.42M | 34.20M |
| Cash from Operations | -126.20M | -135.50M | -126.94M | -121.49M | -95.41M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 84.91M | 56.11M | 87.25M | 150.75M | 72.63M |
| Cash from Investing | 84.91M | 56.11M | 87.25M | 150.75M | 72.63M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 255.00K | 267.00K | 267.00K | 242.00K | 242.00K |
| Repurchase of Common Stock | -485.00K | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -230.00K | 267.00K | 267.00K | 242.00K | 242.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -41.52M | -79.13M | -39.42M | 29.50M | -22.54M |